What dose of nicotinamide riboside do studies and labels give?

Strengths and labels
SourceStrengthPack and directions
NIH label record, one product4300 mg30 vegetarian capsules; the label says one capsule daily, or as recommended by a healthcare practitioner

In an 8-week trial by Conze and colleagues, overweight but otherwise healthy adults, 35 a group, took nicotinamide riboside at 100 mg, 300 mg or 1,000 mg a day or placebo; in a 12-week trial by Dollerup and colleagues (2018), forty obese men took 1,000 mg twice daily or placebo; and EFSA concluded that up to 300 mg a day is safe under the proposed uses for healthy adults, excluding pregnant and lactating women, and that up to 230 mg a day is safe for pregnant and lactating women.123

Strengths and labels

The table is set at the top of the page

No US drug label for nicotinamide riboside turned up in DailyMed, so this strength comes from a supplement label record.

Doses and schedules in trials

The eight trials in this table gave nicotinamide riboside by mouth.

TrialDose and schedulePeopleLength
Conze1100 mg, 300 mg or 1,000 mg a day, or placebo, as 4 capsules daily after breakfast35 a group, overweight but otherwise healthy adults8 weeks
Martens5500 mg twice a day with meals, morning and evening, against placebo30 randomised, healthy middle-aged and older adults6 weeks per phase, crossover
Trammell6a single morning dose of 100 mg, 300 mg or 1,000 mg, overnight fasted, on 3 test days separated by 7-day periods without supplement12 healthy adults36 days of observation
Elhassan 201971 g a day as 250 mg capsules, two in the morning and two in the evening, against placebotwelve aged men21 days per phase, 21-day washout, crossover
Remie81,000 mg a day against placebothirteen healthy overweight or obese men and women completed6 weeks
Dollerup 201821,000 mg twice daily (2,000 mg a day) or placeboforty obese men12 weeks
NADPARK, Brakedal 202291,000 mg by mouth or placebothirty newly diagnosed, treatment-naive Parkinson's patients30 days
Norheim101 g twice a day with meals, morning and evening, or placebo40 patients with stable COPD, plus 20 lung-healthy controls6 weeks, 12-week follow-up

The N-DOSE AD registry entry (NCT05617508) lists placebo, 1,000 mg daily for 12 weeks taken as 500 mg twice daily, or 1,000, 2,000 and 3,000 mg daily across weeks 1-4, 5-8 and 9-12 taken as 500 mg, 1,000 mg and 1,500 mg twice daily, in 80 people with Alzheimer's disease; the entry lists the study as completed, with no results in the registry.11 A stepwise study by Simic and colleagues (2020) of nicotinamide riboside plus pterostilbene stepped from 250/50 mg to 1,000/200 mg twice a day, 2 days per step, in 24 hospitalised patients with acute kidney injury, 5 on the combination and 1 on placebo per step.12

Upper limits from regulators and trials

EFSA's panel concluded nicotinamide riboside chloride is safe under the proposed uses up to 300 mg a day for healthy adults, excluding pregnant and lactating women, and up to 230 mg a day for pregnant and lactating women.3 ChromaDex, the notifier behind FDA's GRAS letter, estimated an upper tolerable intake level of 3 mg/kg bw/day, or 180 mg a day assuming a body weight of 60 kg, by applying a 100-fold safety factor to the no-observed adverse-effect level from a 90-day study in rats.13

Dollerup and colleagues (2018), in forty obese men, concluded that 12 weeks of nicotinamide riboside at 2,000 mg a day appears safe, but does not improve insulin sensitivity and whole-body glucose metabolism in obese, insulin-resistant men.2 The Conze trial, with 140 overweight but otherwise healthy adults enrolled and given 100 mg, 300 mg or 1,000 mg a day or placebo for 8 weeks, reported no flushing and no significant difference in adverse events between nicotinamide riboside and placebo or between doses.1

Storage

The NIH label record for one product says to store it tightly closed in a cool, dry place.4 The applicant's storage advice in EFSA's opinion is refrigerated, which differs from the label record's cool, dry place.3 The FDA letter gives the notifier's data that powdered nicotinamide riboside is stable for up to 11 months under ambient conditions (25°C and 60% relative humidity), and in solution at 4ºC for up to 83 days.13 These are the notifier's stability figures for the ingredient; no label or leaflet found gives storage for a mixed powder.

Frequently asked questions

Is nicotinamide riboside taken with food?

Trials differ: capsules after breakfast in the Conze trial, with meals in the Martens trial and the Norheim COPD trial, and single doses overnight fasted in the Trammell study.15610 None of the trial texts found compared fed and fasted, and the product label record found has no statement on food.

Are there cycles or breaks for nicotinamide riboside?

Searches of the trial registry and PubMed turned up nothing describing cycles or breaks, and no human trial of a cycle schedule.

How do you mix nicotinamide riboside powder?

Searches of the label database, PubMed, the FDA letter and the EFSA opinion turned up no instructions on which liquid or how much.

References

  1. Journal article (PubMed). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. 2019. pmc.ncbi.nlm.nih.gov
  2. Journal article (PubMed). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. 2018. pubmed.ncbi.nlm.nih.gov
  3. EFSA Journal. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. 2019. pmc.ncbi.nlm.nih.gov
  4. NIH Dietary Supplement Label Database (product label). Read the entire label and follow the directions carefully. api.ods.od.nih.gov
  5. Journal article (PubMed). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults. 2018. pmc.ncbi.nlm.nih.gov
  6. Journal article (PubMed). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. 2016. pmc.ncbi.nlm.nih.gov
  7. Journal article (PubMed). Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. 2019. pmc.ncbi.nlm.nih.gov
  8. Journal article (PubMed). Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. 2020. pmc.ncbi.nlm.nih.gov
  9. Journal article (PubMed). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. 2022. pubmed.ncbi.nlm.nih.gov
  10. Journal article (PubMed). Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. 2024. pmc.ncbi.nlm.nih.gov
  11. ClinicalTrials.gov. NCT05617508: N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease. 2025. clinicaltrials.gov
  12. Journal article (PubMed). Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI. 2020. pmc.ncbi.nlm.nih.gov
  13. FDA. Agency Response Letter GRAS Notice GRN 635. fda.gov